Different Mutations of the Human C-mpl Gene Indicate Distinct Haematopoietic Diseases

Overview

Journal J Hematol Oncol

Publisher Biomed Central

Specialties Hematology
Oncology

Date 2013 Jan 29

PMID 23351976

Citations 16

Authors

Xin He

Zhigang Chen

Yangyan Jiang

Xi Qiu

Xiaoying Zhao

Affiliations

Soon will be listed here.

Abstract

The human c-mpl gene (MPL) plays an important role in the development of megakaryocytes and platelets as well as the self-renewal of haematopoietic stem cells. However, numerous MPL mutations have been identified in haematopoietic diseases. These mutations alter the normal regulatory mechanisms and lead to autonomous activation or signalling deficiencies. In this review, we summarise 59 different MPL mutations and classify these mutations into four different groups according to the associated diseases and mutation rates. Using this classification, we clearly distinguish four diverse types of MPL mutations and obtain a deep understand of their clinical significance. This will prove to be useful for both disease diagnosis and the design of individual therapy regimens based on the type of MPL mutations.

Citing Articles

Epigenomic and phenotypic characterization of DEGCAGS syndrome.

Karimi K, Weis D, Aukrust I, Hsieh T, Horackova M, Paulsen J Eur J Hum Genet. 2024; 32(12):1574-1582.

PMID: 39424669 PMC: 11606972. DOI: 10.1038/s41431-024-01702-y.

In Silico Evaluation of Coding and Non-Coding nsSNPs in the Thrombopoietin Receptor () Proto-Oncogene: Assessing Their Influence on Protein Stability, Structure, and Function.

Al-Nakhle H, Yagoub H, Anbarkhan S, Alamri G, Alsubaie N Curr Issues Mol Biol. 2023; 45(12):9390-9412.

PMID: 38132435 PMC: 10742084. DOI: 10.3390/cimb45120589.

Studying the pathogenicity of 26 variants characterized in the first molecular analyses of Egyptian aplastic anemia patients.

Sokkar M, Hamdy M, Erian P, Mosaad R, Elaraby N, Taher M J Genet Eng Biotechnol. 2023; 21(1):149.

PMID: 38017244 PMC: 10684839. DOI: 10.1186/s43141-023-00585-8.

Additional Genetic Alterations and Clonal Evolution of MPNs with Double Mutations on the Gene: Two Case Reports.

Pennisi M, Di Gregorio S, Tirro E, Romano C, Duminuco A, Garibaldi B Hematol Rep. 2023; 15(2):317-324.

PMID: 37367082 PMC: 10298502. DOI: 10.3390/hematolrep15020033.

ANKRD26 is a new regulator of type I cytokine receptor signaling in normal and pathological hematopoiesis.

Basso-Valentina F, Donada A, Manchev V, Lisetto M, Balayn N, Martin J Haematologica. 2023; 108(8):2130-2145.

PMID: 36794499 PMC: 10388282. DOI: 10.3324/haematol.2022.282049.

References

Ballmaier M, Germeshausen M, Schulze H, Cherkaoui K, Lang S, Gaudig A . c-mpl mutations are the cause of congenital amegakaryocytic thrombocytopenia. Blood. 2001; 97(1):139-46. DOI: 10.1182/blood.v97.1.139. View

Ritchie A, Braun S, He J, Broxmeyer H . Thrombopoietin-induced conformational change in p53 lies downstream of the p44/p42 mitogen activated protein kinase cascade in the human growth factor-dependent cell line M07e. Oncogene. 1999; 18(7):1465-77. DOI: 10.1038/sj.onc.1202439. View

Teofili L, Giona F, Martini M, Cenci T, Guidi F, Torti L . Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia. J Clin Oncol. 2007; 25(9):1048-53. DOI: 10.1200/JCO.2006.08.6884. View

Ballmaier M, Germeshausen M . Congenital amegakaryocytic thrombocytopenia: clinical presentation, diagnosis, and treatment. Semin Thromb Hemost. 2011; 37(6):673-81. DOI: 10.1055/s-0031-1291377. View

Guglielmelli P, Pancrazzi A, Bergamaschi G, Rosti V, Villani L, Antonioli E . Anaemia characterises patients with myelofibrosis harbouring Mpl mutation. Br J Haematol. 2007; 137(3):244-7. DOI: 10.1111/j.1365-2141.2007.06565.x. View

Tijssen M, Di Summa F, van den Oudenrijn S, Zwaginga J, van der Schoot C, Voermans C . Functional analysis of single amino-acid mutations in the thrombopoietin-receptor Mpl underlying congenital amegakaryocytic thrombocytopenia. Br J Haematol. 2008; 141(6):808-13. DOI: 10.1111/j.1365-2141.2008.07139.x. View

Pikman Y, Lee B, Mercher T, McDowell E, Ebert B, Gozo M . MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med. 2006; 3(7):e270. PMC: 1502153. DOI: 10.1371/journal.pmed.0030270. View

Pardanani A, Lasho T, Finke C, Markovic S, Tefferi A . Demonstration of MPLW515K, but not JAK2V617F, in in vitro expanded CD4+ T lymphocytes. Leukemia. 2007; 21(10):2206-7. DOI: 10.1038/sj.leu.2404749. View

Hong Y, Dumenil D, van der Loo B, Goncalves F, Vainchenker W, Erusalimsky J . Protein kinase C mediates the mitogenic action of thrombopoietin in c-Mpl-expressing UT-7 cells. Blood. 1998; 91(3):813-22. View

10.

Matthews E, Thevenin D, Rogers J, Gotow L, Lira P, Reiter L . Thrombopoietin receptor activation: transmembrane helix dimerization, rotation, and allosteric modulation. FASEB J. 2011; 25(7):2234-44. PMC: 3114528. DOI: 10.1096/fj.10-178673. View

11.

Tefferi A, Vardiman J . Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia. 2007; 22(1):14-22. DOI: 10.1038/sj.leu.2404955. View

12.

Kaushansky K, Lok S, Holly R, Broudy V, Lin N, BAILEY M . Promotion of megakaryocyte progenitor expansion and differentiation by the c-Mpl ligand thrombopoietin. Nature. 1994; 369(6481):568-71. DOI: 10.1038/369568a0. View

13.

Pallard C, Gouilleux F, Benit L, Cocault L, Souyri M, Levy D . Thrombopoietin activates a STAT5-like factor in hematopoietic cells. EMBO J. 1995; 14(12):2847-56. PMC: 398403. DOI: 10.1002/j.1460-2075.1995.tb07284.x. View

14.

Vigon I, Mornon J, Cocault L, Mitjavila M, Tambourin P, Gisselbrecht S . Molecular cloning and characterization of MPL, the human homolog of the v-mpl oncogene: identification of a member of the hematopoietic growth factor receptor superfamily. Proc Natl Acad Sci U S A. 1992; 89(12):5640-4. PMC: 49348. DOI: 10.1073/pnas.89.12.5640. View

15.

Verstovsek S, Kantarjian H, Mesa R, Pardanani A, Cortes-Franco J, Thomas D . Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med. 2010; 363(12):1117-27. PMC: 5187954. DOI: 10.1056/NEJMoa1002028. View

16.

Schnittger S, Bacher U, Haferlach C, Beelen D, Bojko P, Burkle D . Characterization of 35 new cases with four different MPLW515 mutations and essential thrombocytosis or primary myelofibrosis. Haematologica. 2008; 94(1):141-4. PMC: 2625421. DOI: 10.3324/haematol.13224. View

17.

Ihara K, Ishii E, Eguchi M, Takada H, Suminoe A, GOOD R . Identification of mutations in the c-mpl gene in congenital amegakaryocytic thrombocytopenia. Proc Natl Acad Sci U S A. 1999; 96(6):3132-6. PMC: 15907. DOI: 10.1073/pnas.96.6.3132. View

18.

Zhao W, Du Y, Ho W, Fu X, Zhao Z . JAK2V617F and p53 mutations coexist in erythroleukemia and megakaryoblastic leukemic cell lines. Exp Hematol Oncol. 2012; 1(1):15. PMC: 3514099. DOI: 10.1186/2162-3619-1-15. View

19.

Wernig G, Kharas M, Mullally A, Leeman D, Okabe R, George T . EXEL-8232, a small-molecule JAK2 inhibitor, effectively treats thrombocytosis and extramedullary hematopoiesis in a murine model of myeloproliferative neoplasm induced by MPLW515L. Leukemia. 2011; 26(4):720-7. DOI: 10.1038/leu.2011.261. View

20.

Ding J, Komatsu H, Wakita A, Kato-Uranishi M, Ito M, Satoh A . Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin. Blood. 2004; 103(11):4198-200. DOI: 10.1182/blood-2003-10-3471. View